Clinical trial
Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial…
NCT00468767 · Advanz Pharma, Industry · Completed
Key facts
| NCT number | NCT00468767 |
|---|---|
| Title | Phase III Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation |
| Official title | A Phase III Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Centred Tolerance and Efficacy Study of RSD1235 in Patients With Atrial Fibrillation |
| Acronym | ACT I |
| Lead sponsor | Advanz Pharma, Industry |
| Collaborators | Astellas Pharma US, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Vernakalant Injection 20 mg/mL |
| Enrollment | 356 |
| Start date | Aug 1, 2003 |
| Primary completion | Nov 1, 2004 |
| Completion | Nov 1, 2004 |
| First posted | May 3, 2007 |
| Last update posted | Apr 2, 2008 |
| Countries | Canada, Denmark, Sweden, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: